ASX Growth Stocks With Strong Insider Ownership
As Australian shares take a positive cue from Wall Street, the market remains cautious amid concerns of rising interest rates following unexpected inflation data. In this environment, growth companies with significant insider ownership can stand out as they often signal confidence in the business's potential and alignment with shareholder interests.
Top 10 Growth Companies With High Insider Ownership In Australia
| Name | Insider Ownership | Earnings Growth |
| Wisr (ASX:WZR) | 15.7% | 97.8% |
| Starpharma Holdings (ASX:SPL) | 17.3% | 75.1% |
| SKS Technologies Group (ASX:SKS) | 14.7% | 28.3% |
| PDI Gold (ASX:PDI) | 11.1% | 62.3% |
| Innovaero Technologies (ASX:INN) | 37.9% | 66.2% |
| Forrestania Resources (ASX:FRS) | 24.8% | 72.9% |
| Barton Gold Holdings (ASX:BGD) | 20.8% | 86.7% |
| Austral Resources Australia (ASX:AR1) | 22.6% | 28.2% |
| Adveritas (ASX:AV1) | 17.1% | 99.9% |
| Advanced Engineered Materials (ASX:AEM) | 35.2% | 58.7% |
Here's a peek at a few of the choices from the screener.
Echo IQ (ASX:EIQ)
Simply Wall St Growth Rating: ★★★★★☆
Overview: Echo IQ Limited is an Australian AI and medical technology company focused on developing AI solutions for cardiac diagnostics, with a market cap of A$407.40 million.
Operations: The company generates revenue from the development of artificial intelligence software, amounting to A$0.09 million.
Insider Ownership: 16.5%
Earnings Growth Forecast: 53.6% p.a.
Echo IQ's high insider ownership aligns with its rapid growth potential, as revenue is forecast to grow 97.2% annually, surpassing market averages. Despite a net loss of A$18.57 million for the year ending June 2026, the company expects profitability within three years. Recent board enhancement with Scott Wilkin supports US expansion efforts. However, the company's low revenue base and volatile share price may present challenges amidst its ambitious growth trajectory and strategic shifts in index inclusion.
- Get an in-depth perspective on Echo IQ's performance by reading our analyst estimates report here.
- Our valuation report unveils the possibility Echo IQ's shares may be trading at a premium.
Guzman y Gomez (ASX:GYG)
Simply Wall St Growth Rating: ★★★★★☆
Overview: Guzman y Gomez Limited operates and manages quick service restaurants in Australia, Singapore, and Japan with a market cap of A$2.47 billion.
Operations: The company generates revenue of A$551.75 million from its quick service restaurant operations across Australia, Singapore, and Japan.
Insider Ownership: 16.5%
Earnings Growth Forecast: 20.5% p.a.
Guzman y Gomez displays significant growth potential with earnings forecasted to grow 20.5% annually, outpacing the Australian market's 11.3%. Despite a net loss of A$26.7 million in the last fiscal year, the company plans to open 35 new restaurants in Australia by FY2027, supporting its expansion strategy. The ongoing share repurchase program worth A$100 million aims to enhance shareholder returns while sustaining growth ambitions, although revenue growth is expected at a slower pace of 13.9% per year.
- Click here and access our complete growth analysis report to understand the dynamics of Guzman y Gomez.
- Upon reviewing our latest valuation report, Guzman y Gomez's share price might be too optimistic.
Mesoblast (ASX:MSB)
Simply Wall St Growth Rating: ★★★★★☆
Overview: Mesoblast Limited, along with its subsidiaries, focuses on developing regenerative medicine products in Australia and has a market cap of A$3.01 billion.
Operations: The company's revenue is primarily derived from the development and commercialization of its allogeneic cellular medicines platform, amounting to $120.25 million.
Insider Ownership: 34.2%
Earnings Growth Forecast: 53.9% p.a.
Mesoblast exhibits strong growth potential, with revenue forecasted to grow 37.6% annually, significantly outpacing the Australian market. Recent FDA approval of a new assay for Ryoncil enhances product consistency and effectiveness, supporting its commercial success. Despite a net loss of US$57.5 million in FY2026, revenue surged to US$120.25 million from US$17.2 million the previous year. The company is on track for profitability within three years, driven by innovative product developments and strategic market positioning.
- Unlock comprehensive insights into our analysis of Mesoblast stock in this growth report.
- The valuation report we've compiled suggests that Mesoblast's current price could be inflated.
Seize The Opportunity
- Dive into all 120 of the Fast Growing ASX Companies With High Insider Ownership we have identified here.
- Curious About Other Options? Uncover the next big thing with financially sound penny stocks that balance risk and reward.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com